Cable Hill Partners LLC Sells 202 Shares of Johnson & Johnson (NYSE:JNJ)

Cable Hill Partners LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,322 shares of the company’s stock after selling 202 shares during the quarter. Johnson & Johnson makes up approximately 0.5% of Cable Hill Partners LLC’s portfolio, making the stock its 17th largest holding. Cable Hill Partners LLC’s holdings in Johnson & Johnson were worth $2,195,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in JNJ. Arrowstreet Capital Limited Partnership raised its position in shares of Johnson & Johnson by 42.6% in the first quarter. Arrowstreet Capital Limited Partnership now owns 9,004,994 shares of the company’s stock valued at $1,479,971,000 after purchasing an additional 2,688,957 shares during the period. Franklin Resources Inc. raised its position in shares of Johnson & Johnson by 15.8% in the second quarter. Franklin Resources Inc. now owns 16,118,269 shares of the company’s stock valued at $2,655,321,000 after purchasing an additional 2,197,757 shares during the period. Vanguard Group Inc. raised its position in shares of Johnson & Johnson by 0.7% in the second quarter. Vanguard Group Inc. now owns 231,432,368 shares of the company’s stock valued at $38,126,168,000 after purchasing an additional 1,701,721 shares during the period. BlackRock Inc. grew its stake in shares of Johnson & Johnson by 0.9% in the second quarter. BlackRock Inc. now owns 191,385,110 shares of the company’s stock worth $31,528,781,000 after acquiring an additional 1,694,112 shares during the last quarter. Finally, Canada Pension Plan Investment Board grew its stake in shares of Johnson & Johnson by 55.4% in the first quarter. Canada Pension Plan Investment Board now owns 4,730,681 shares of the company’s stock worth $777,487,000 after acquiring an additional 1,685,664 shares during the last quarter. 67.29% of the stock is currently owned by institutional investors.

JNJ traded up $1.70 during trading on Thursday, reaching $160.90. 157,987 shares of the company’s stock were exchanged, compared to its average volume of 7,040,690. Johnson & Johnson has a fifty-two week low of $133.65 and a fifty-two week high of $179.92. The company has a quick ratio of 1.13, a current ratio of 1.39 and a debt-to-equity ratio of 0.44. The business has a 50 day moving average price of $168.96 and a 200 day moving average price of $167.54. The company has a market capitalization of $423.57 billion, a P/E ratio of 23.94, a PEG ratio of 2.23 and a beta of 0.71.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 20th. The company reported $2.48 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.29 by $0.19. Johnson & Johnson had a net margin of 19.92% and a return on equity of 37.06%. The firm had revenue of $23.31 billion for the quarter, compared to the consensus estimate of $22.54 billion. During the same quarter in the previous year, the company earned $1.67 earnings per share. The business’s revenue was up 27.1% compared to the same quarter last year. As a group, research analysts forecast that Johnson & Johnson will post 9.65 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 7th. Stockholders of record on Tuesday, August 24th were paid a $1.06 dividend. The ex-dividend date of this dividend was Monday, August 23rd. This represents a $4.24 annualized dividend and a dividend yield of 2.64%. Johnson & Johnson’s dividend payout ratio is presently 52.80%.

Several equities research analysts have recently issued reports on JNJ shares. Morgan Stanley downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 price objective on the stock. in a research note on Tuesday, September 7th. SVB Leerink restated a “buy” rating on shares of Johnson & Johnson in a research note on Thursday, July 29th. Finally, Wells Fargo & Company restated a “buy” rating on shares of Johnson & Johnson in a research note on Thursday, October 7th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has an average rating of “Buy” and a consensus price target of $190.38.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Article: Mutual funds are not immune from market timing

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.